This study is 8 weeks long and involves subjects taking memantine or placebo. If they are
randomly assigned to the memantine arm and are eligible to participate in the study, they
will begin by taking 10mg once daily of memantine for two weeks, then 20mg for the remaining
six weeks. Efficacy and safety measures will be performed at each visit. Participants will be
randomized to receive either memantine or placebo on a 1:1 basis. This blinding will be
maintained by the IDS pharmacy at the University of Chicago.